Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 102

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 102
---
 exercise of such warrants. See “Plan of Distribution.”

<div align='center'>64</div>

UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in this registration statement, unless defined below. As used in this unaudited pro forma combined financial information, “Liminatus” refers to Liminatus Pharma, LLC, a Delaware limited liability company, “ParentCo” refers to Iris Parent Holding Corp. (now known as Liminatus Pharma, Inc.), a Delaware corporation, and “Iris” refers to Iris Acquisition Corp (formerly Tribe Capital Growth Corp I) prior to the Business Combination. The unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S-X and presents the combination of the historical financial information of Iris, Liminatus, and ParentCo, adjusted to give effect to the Business Combination and the other events contemplated by the Business Combination Agreement. Unless otherwise indicated or the context otherwise requires, references to the “Combined Company” refer to ParentCo and its consolidated subsidiaries after giving effect to the Business Combination. The unaudited pro forma combined balance sheet as of March 31, 2025 combines the historical balance sheets of Iris, ParentCo, and Liminatus on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on March 31, 2025. The unaudited pro forma combined statement of operations for the three months ended March 31, 2025 and the year ended December 31, 2024, combines the historical statements of operations of Iris, Liminatus and ParentCo on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on January 1, 2024, the beginning of the earliest period presented. The unaudited pro forma combined balance sheet as of March 31, 2025 and unaudited pro forma combined statement of operations for the three months ended March 31, 2025 has been derived from and should be read in conjunction with the following:

The unaudited pro forma combined statement of operations for the year ended December 31, 2024 has been derived from and should be read in conjunction with the following:

The unaudited pro forma combined financial information should also be read together with the sections of the financial statements of Iris as of and for the three months ended March